Pipeline

Pipeline

Product CandidateIndicationPreclinicalEarly-Stage ClinicalLate-Stage Clinical
Nana-val (nanatinostat + valganciclovir)
Relapsed/Refractory EBV+ Lymphoma

Nana-val
Relapsed/Refractory EBV+ Solid Tumors

Nanatinostat Combination
Other Virus-associated Malignancies

Vecabrutinib Non-covalent ITK/BTK inhibitor
Immuno-oncology combination - Multiple Undisclosed

VRx-510 PDK-1 inhibitor
Oncology – Multiple Undisclosed

Product CandidateIndicationStage
Nana-val (nanatinostat + valganciclovir) Relapsed/Refractory EBV+ Lymphoma Late-Stage Clinical

Nana-val Relapsed/Refractory EBV+ Solid Tumors Early-Stage Clinical

Nanatinostat Combination Other Virus-associated Malignancies Preclinical

Vecabrutinib Non-covalent ITK/BTK inhibitor Immuno-oncology combination - Multiple Undisclosed Early-Stage Clinical

VRx-510 PDK-1 inhibitor Oncology – Multiple Undisclosed Preclinical

*VRx-510 – PDK-1 inhibitor, formerly SNS-510

Regulatory Status


The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies.

    Orphan Drug Designations granted for nanatinostat with valganciclovir for the treatment of:
  • T-cell lymphoma
  • Post-transplant lymphoproliferative disorder (PTLD)
  • Plasmablastic lymphoma

Viracta has initiated a clinical trial to treat EBV+ lymphomas. For more information about the trial, see ClinicalTrials.gov.
Contact: clinicaltrials@viracta.com

Viracta has an Expanded Access Policy in compliance with the 21st Century Cures Act.